Emerging therapies for angina: new modalities may offer additional clinical options.
The social and economic burdens of chronic angina are enormous, and the morbidity and mortality associated with its underlying cause, coronary artery disease, are high. For many patients with chronic angina, current drug therapies are contraindicated or ineffective, and surgical procedures too risky or costly. Most newer approaches have not yet been sufficiently evaluated and can be expensive, time-consuming, or both. A new class of antianginal drugs, the metabolic modulators, will soon be available. In controlled clinical trials, these agents have shown promising results in reducing the frequency of angina episodes and lengthening the duration of exercise sessions. They are also well tolerated.
Schroeder
John Speer
JS
Stanford University School of Medicine, Falk Cardiovascular Research Center, Stanford, California 94305, USA. hf.cxv@forsythe.stanford.edu
D000787:Angina Pectoris / Q000188:drug therapy* / Q000191:economics / Q000453:epidemiology / Q000517:prevention & control; D002317:Cardiovascular Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D008660:Metabolism / Q000187:drug effects; D014481:United States
D002317:Cardiovascular Agents